Columna Capital: Investment Strategy, Funds, Portfolio Companies, and Firm Profile
1. What Is Columna Capital?
Columna Capital is a London-headquartered private equity firm established in 2009. Its co-founders are Rory Devlin, Vilmos Pongracz, and Michael Tose. The firm invests in European lower-middle-market businesses and works with entrepreneurs and management teams to support their development.
Its investment approach combines a concentrated portfolio, management participation, organic expansion, and acquisition-led growth. France, Italy, Spain, and Switzerland are explicitly identified as core markets. Its principal sector categories are healthcare, animal health, insurance and business services, and agri-food.
For directory purposes, Columna is best classified under direct private equity and buyouts, with additional descriptors of lower-middle-market investing and regional European specialization. Its use of continuation vehicles adds flexibility to investment duration, but does not make it primarily a secondaries manager or permanent-capital holding company. These are editorial classifications based on its documented investment activities.
2. Columna Capital at a Glance
- Firm name
- Columna Capital.
- Firm type
- European lower-middle-market private equity firm.
- Founded
- 2009. A separate founding-city designation has not been verified.
- Founders
- Rory Devlin, Vilmos Pongracz, and Michael Tose.
- Headquarters
- London, United Kingdom.
- Parent organization
- Partner-led Columna group; no larger corporate parent verified.
- Main investment markets
- Continental Europe, particularly France, Italy, Spain, and Switzerland.
- Geography group
- Europe.
- Directory segments
- Direct private equity / buyouts; control buyouts; lower-middle-market investors; regional private equity specialists.
- Principal strategies
- Growth-oriented direct equity investments, buy-and-build, organic expansion, and continuation structures.
- Ownership preference
- Predominantly majority investments, with flexibility to maintain minority exposure after recapitalizations.
- Typical company profile
- Entrepreneur-led businesses with significant growth potential; recent firm descriptions identify companies with revenue up to €100 million.
- Sector focus
- Healthcare and well-being; animal health; financial and business services; agri-food.
- Important funds and vehicles
- Fund III and company-specific continuation structures. Fund IV is identifiable in 2026 pre-marketing records, without a verified final-close amount.
- Current status
- Operating investment firm led by five partners, including Managing Partner Rory Devlin.
- Official website
- Columna Capital Official Website
3. Who Founded Columna Capital, and How Is the Firm Organized?
Columna Capital was founded in 2009 by Rory Devlin, Vilmos Pongracz, and Michael Tose. London is its documented headquarters. The available founding history does not separately establish a founding city, so the headquarters location should not automatically be treated as a distinct historical founding-location disclosure.
The founders brought different professional backgrounds. Devlin previously worked at ESO Capital and D.B. Zwirn and was CFO and co-founder of Surplex. Pongracz previously held roles at BlackRock, Lone Star, and Morgan Stanley. Tose’s background includes ESO Capital, FTI Consulting, PwC, and financial management. These backgrounds help explain the combination of investment, financing, and operational experience represented in the partnership, without establishing that every capability is deployed at every portfolio company.
The firm was described as partner-owned in March 2024. Its current partner group comprises the three co-founders, Andrea Frecchiami, and Charles Nantois. Nantois’s promotion to partner was announced on July 28, 2026. Devlin remains identified as Managing Partner.
The operating brand also encompasses distinct legal entities. Columna’s regulatory description identifies Columna Capital LLP as the British investment adviser to CPL Guernsey Limited, which manages and advises investment vehicles. Luxembourg entities include Columna Capital Luxembourg and separate general-partner companies. Those entities should not be confused with the underlying funds or portfolio businesses.
4. What Is the History of Columna Capital?
Columna’s development is a progression from individual investment sponsorship to institutional funds, alongside structures that allow selected company relationships to continue beyond an original fund’s realization. Six milestones help explain that development.
- 2009: establishment and initial investment sponsorship. The firm began investing on a deal-by-deal basis. Its partners subsequently described five investments made before the launch of its first institutional fund. This distinguishes the founding of the business from the later introduction of the numbered fund series.
- 2016 to 2018: development of the flagship fund series. Columna’s maiden fund launched in 2016. Public fund records identify Fund I’s close in March 2017 and Fund II’s close in September 2018. Launch dates and final-close dates are therefore not interchangeable.
- 2021 to 2022: continuation structures and Fund I realization. Datamars and Bianalisi were transferred into Columna-managed single-asset structures in 2021. A subsequent Santévet transaction completed Fund I’s realization, announced on March 4, 2022, while preserving Columna-managed investment exposure to the business.
- 2023: further platform investments. Physidia announced a completed investment from Columna on May 31, 2023. Zumex announced its partnership with Columna on October 10, 2023, identifying the firm as its new majority shareholder and first institutional investor.
- 2024: Fund III’s final close and an Italian office. Fund III’s €290 million commitments announcement was published on June 20, 2024. The opening of a Milan office followed on November 1, joining the firm’s London and Luxembourg locations.
- 2026: partnership development and a completed dental-platform exit. Nantois became a partner in July. Columna then sold its majority shareholding in Ardentis to Medbase in a transaction that closed on August 14, 2026.
Analytically, these milestones show that Columna’s long-term partnership language is compatible with realizations and changes in investment vehicle. An extended relationship with a company does not imply that its original fund remains invested indefinitely.
5. What Investment Strategies Does Columna Capital Pursue?
Columna pursues growth-oriented direct private equity. Its stated approach is to identify off-market opportunities, invest in a limited number of businesses, and work closely with their founders and management teams. Organic development and strategic acquisitions are complementary elements of the model, rather than separate explanations for unrelated investment businesses.
Majority ownership has been its usual starting position. The partners have also described transactions combining shareholder liquidity with new capital for business expansion. Consequently, “buyout” describes an important ownership mechanism, while growth investment describes a substantial part of the intended use of capital. Neither term alone fully captures the proposition.
Physidia illustrates the combination: Columna completed an investment while the existing family and founders remained minority shareholders, and the announced purpose was to support the company’s next growth phase. Zumex’s 2023 announcement similarly combined a new institutional majority shareholder with founder participation. These are established operating businesses, not evidence of a broad early-stage venture mandate.
Ownership can evolve. Bianalisi was described as a retained minority investment in 2024. The January 2026 MSA Mizar transaction announcement also provided for Columna to reinvest and retain a significant minority interest alongside a new majority investor. Such relationships require firm-level ownership to be distinguished from continued control.
Continuation structures provide another dimension: they can supply liquidity to an earlier fund while preserving the manager’s relationship with a company and financing a further development period.
6. What Funds Does Columna Capital Manage?
Columna’s publicly identifiable structure includes a numbered flagship fund series and company-specific investment vehicles. Those vehicles serve different purposes and should not be added together as though every disclosed amount measures the same pool of capital.
- Columna Capital Fund I: the maiden fund launched in 2016. Columna announced its full realization on March 4, 2022, following the Santévet transfer. That fund-level realization did not establish a complete firm-level exit from every transferred business.
- Columna Capital Fund II: an identifiable historical flagship vehicle, with public fund records listing a September 2018 close. A final-close commitment amount has not been verified for this profile.
- Columna Capital Fund III: Columna announced its final close on June 20, 2024, reporting €290 million of commitments. This is a dated fundraising measure, not firm-wide assets under management, portfolio enterprise value, or remaining investment capacity.
- Columna Capital Fund IV SCSp: a Luxembourg vehicle identifiable in regulatory records. Its Swedish pre-marketing notification is dated May 5, 2026. A final close or final-close amount has not been verified, so it is not presented as a completed successor fundraise.
Company-specific continuation arrangements are material to the structure. Columna’s realization announcement identified transfers involving Datamars and Bianalisi in 2021 and Santévet in 2022. The Santévet structure also raised €150 million in committed growth capital. Separately inspected transaction documentation establishes that Fund III participated in the Santévet continuation transaction and that a participating fund housed growth capital.
The legal framework includes advisory, management, and general-partner entities across Britain, Guernsey, and Luxembourg. Their existence does not establish a separate investment strategy, nor does a holding or management company automatically identify the ultimate participating fund.
7. What Types of Companies Does Columna Capital Invest In?
Columna’s recent firm descriptions identify companies with revenue up to €100 million and significant growth potential. Its August 2026 description additionally emphasizes profitability. These statements describe an entry-company profile, not a ceiling on the eventual revenue of an expanded portfolio business.
In March 2024, its partners reported average initial investment tickets of €20 million to €40 million, with further capital reserved for follow-on investment. That historical ticket range is not a newly measured 2026 limit, and it should not be substituted for transaction enterprise value.
The documented examples encompass several business models. Zumex supplies juicing equipment to foodservice and retail customers. Physidia develops and manufactures home dialysis technology. Over operates in long-term care and senior living; a co-investor’s December 2024 disclosure confirmed participation alongside Columna in a September capital increase intended to finance acquisition-led growth.
Founder and management partnerships are particularly visible. Zumex’s announcement identified Columna as its first institutional investor. Physidia’s existing shareholders retained minority positions at the investment. These situations support an interpretation of Columna as a partner for businesses seeking additional capital, organizational development, and expansion without necessarily eliminating entrepreneurial participation.
The inspected examples do not justify declaring public-to-private transactions, corporate carve-outs, or distressed acquisitions to be core contemporary mandates. Nor should the stated company profile be treated as a complete eligibility checklist or evidence of current investment appetite.
8. Which Industries Does Columna Capital Focus On?
Columna identifies four principal sector categories: healthcare, animal health, insurance and business services, and agri-food. These categories cover different revenue models and operating requirements, so the underlying businesses matter more than the category names alone.
Healthcare services and medical technology
Bianalisi establishes substantive exposure to clinical laboratories and imaging centers. Its activities include laboratory services, outpatient diagnostics, and diagnostic imaging. Other healthcare exposure includes Over’s long-term care and senior living activities and Physidia’s home dialysis devices. The portfolio therefore spans service delivery and medical technology rather than a single healthcare business model.
Animal health
Columna’s identified investment businesses include MiVet, a Spanish veterinary clinic and hospital network, providing a direct connection to veterinary services. Datamars adds animal-related technology exposure, alongside textile solutions. These activities should not be described as a uniform animal-pharmaceuticals specialization.
Insurance and business services
Santévet is a pet health insurance platform. MSA Mizar supplies technology-enabled insurance claims management and third-party claims administration. Their inclusion in a shared sector category does not make their business activities interchangeable.
Agri-food and related technology
Zumex designs, manufactures, and commercializes fruit and vegetable juicing equipment. Its exposure is therefore to food-related technology and equipment, rather than necessarily to food production itself. This illustrates why company-level industry descriptions are more precise than copying the investor’s broad sector label.
9. Where Does Columna Capital Invest?
Columna’s headquarters is in London, in the United Kingdom. Its headquarters should be distinguished from its investment geography: the firm’s stated investment focus is principally continental European.
The approach page explicitly identifies France, Switzerland, Italy, and Spain as key markets. An August 2026 firm description uses the broader geographic formulation of Italy, France, Iberia, and Southern DACH. That broader wording should not be interpreted as proof of investment activity in every country encompassed by those regional terms.
The office network has also evolved. Columna announced its Milan office on November 1, 2024, identifying it as its third location alongside London and Luxembourg. The announcement connected the Italian presence with support for existing portfolio companies and opportunities involving entrepreneur-led businesses. Office presence and an investment mandate remain separate concepts.
Portfolio-company expansion can reach beyond the platform’s home market. For example, Zumex’s 2023 transaction announcement described sales in more than 100 countries. That international commercial footprint does not change the geographic classification of Columna’s originating investment business.
Europe is therefore the appropriate directory geography group. Analytically, the more useful description is a continental European lower-middle-market strategy with identifiable country concentrations and cross-border growth ambitions, rather than an undifferentiated global investment mandate.
10. How Does Columna Capital Seek to Create Value?
Columna describes active support encompassing strategic development, important hires, financial optimization, and international expansion. It also introduces prospective founders to its existing founder network. These are firm-described resources and approaches, not independently measured results or proof that every company receives an identical operating program.
Its partners have emphasized integration rather than simply accumulating acquired businesses. The described objective includes revenue and fixed-cost synergies, together with recruitment to strengthen management as smaller businesses develop into larger groups.
Ardentis provides a documented company example. Columna’s exit announcement described a growth strategy involving clinic expansion, acquisitions, reconfiguration of central services, and enlargement of the management team. Those initiatives were intended to improve operating support for the clinics and facilitate further scaling of the integrated platform. They should not be converted into unverified claims about procurement savings, pricing improvements, or investment returns.
Physidia illustrates a different operating agenda. Its investment profile identifies international expansion, continuing product development, and greater awareness of home dialysis among regulatory, corporate, and patient audiences. The emphasis follows the company’s medical-device business model rather than a generic consolidation template.
MSA Mizar’s January 2026 announcement described investment in technology and operating capabilities and plans to strengthen technology and AI-based capabilities. Those statements concern that business and the announced partnership. They do not establish portfolio-wide AI adoption, a central Columna AI operating team, or achieved AI-related financial benefits.
11. What Types of Business Situations May Fit Columna Capital?
The following situations appear consistent with Columna’s documented investments. They are analytical observations, not an assurance that the firm is currently seeking a particular transaction or would be suitable for a specific business.
- An entrepreneur seeking a first institutional equity partner. Zumex’s 2023 announcement identified Columna as its first institutional investor and described continued participation by the founder. That supports a partnership model combining institutional capital with entrepreneurial continuity.
- A healthcare platform requiring further expansion. Bianalisi’s documented acquisition activity and Ardentis’s clinic-development program demonstrate situations involving additional locations, expanded services, and platform development. They do not establish identical operating requirements across healthcare companies.
- A differentiated product business seeking international development. Physidia’s completed investment was intended to support its next growth phase, while its investment strategy identifies product development and market expansion as priorities.
- An existing portfolio relationship requiring another capital phase. Santévet’s continuation transaction combined an earlier fund’s realization with further committed growth capital and participation by Fund III. This illustrates how liquidity and continued company development can coexist.
The common thread is a business-development agenda requiring more than a transfer of shares. However, none of these examples supplies a complete current underwriting checklist, minimum profitability threshold, or commitment to finance every expansion opportunity.
12. What Distinguishes Columna Capital?
Several characteristics provide a more precise understanding of Columna’s proposition than the general label “European private equity.”
- A deliberately concentrated approach. The firm states that a limited portfolio allows deeper engagement and more detailed market understanding. Concentration is an operating choice, not evidence of superior performance.
- Identifiable continental European concentrations. Its Milan office announcement connects local presence with entrepreneur-led opportunities and support for existing Italian investments. This gives substance to its regional orientation without implying equal coverage of every European market.
- Economic participation alongside investment partners. Columna’s partners have described team co-investment and meaningful general-partner commitments. This is an alignment mechanism; it does not eliminate investment risk or guarantee an outcome.
- Flexibility in the duration of selected relationships. Its documented continuation transactions distinguish the life of an individual fund from the life of a company partnership. Such structures can preserve manager involvement after an earlier fund realizes its investment.
Analytically, the combination is a growth-oriented buyout model with selective longer-duration investment relationships. It should not be confused with an evergreen holding company simply because some partnerships continue across vehicles. Nor does the combination establish an advantage over other firms without comparative evidence.
13. How Should Columna Capital Be Understood Today?
As reviewed on October 13, 2026, Columna is best understood as a European lower-middle-market private equity firm built around entrepreneurial partnerships and business expansion. Its recent descriptions continue to emphasize growth potential, organic development, and acquisition-led expansion across its principal sectors.
The organization has developed an institutional fund series, company-specific continuation structures, and a Milan presence. Fund III’s June 20, 2024 announcement remains the verified €290 million final-close commitments reference used in this profile. Fund IV is identifiable in 2026 pre-marketing documentation, but a completed final close is not verified here. Neither fact establishes current dry powder or transaction appetite.
Ownership changes also matter. The completed Ardentis sale places that business in the former portfolio rather than the current selection. Separately, Columna’s May 5, 2026 Evidenze announcement described a binding acquisition agreement subject to regulatory approvals. A completed closing was not verified for this profile, so Evidenze is not added as a current portfolio company.
The directory classification is therefore direct private equity and buyouts, qualified by lower-middle-market scale, European specialization, and flexible continuation relationships. Inclusion in Umbrex’s “Top 1000 Global Private Equity Firms” identifies the research collection. It is not a verified ranking or evidence of investment quality, superior returns, fundraising strength, or suitability for a particular company.
14. Frequently Asked Questions
Is Columna Capital a buyout firm or a venture capital firm?
Columna is principally a lower-middle-market direct private equity investor. Majority investments, established businesses, and acquisition-led development are central to the documented model. Its growth orientation should not be mistaken for a broad early-stage venture strategy.
Who founded Columna Capital?
The co-founders are Rory Devlin, Vilmos Pongracz, and Michael Tose. The firm was established in 2009. Devlin is identified as Managing Partner, while Pongracz and Tose remain identified as partners.
Where does Columna Capital primarily invest?
Its stated core markets include France, Italy, Spain, and Switzerland. Recent descriptions also use Iberia and Southern DACH. London is the headquarters, which is distinct from the continental European investment focus.
What is the verified Fund III fundraising amount?
Columna announced €290 million of commitments at Fund III’s final close on June 20, 2024. The amount is not firm-wide assets under management. Fund IV’s 2026 pre-marketing record does not establish a completed successor fundraise.
Does realization of Fund I mean Columna exited all its underlying companies?
No. Columna’s realization announcement described transfers of Datamars, Bianalisi, and Santévet into Columna-managed structures. Fund-level realization and firm-level ownership are different questions, and continuing exposure must be assessed separately.
Why is Ardentis classified as a former portfolio company?
Columna sold its majority shareholding to Medbase in a transaction that closed on August 14, 2026. Ardentis management retained a minority interest, which should not be confused with continued ownership by Columna.